Company intelligence / Profile preview

Vida Ventures

Boston, Massachusetts, United Statesvidaventures.com ↗

Ownership: Private
Employees: ~35
Development stage: Other

Overview

Vida Ventures does not develop drugs or run clinical trials itself. Its investments support biotech firms with programs ranging from preclinical to Phase 3/commercial stages across oncology, immunology/autoimmune disorders, neurology and rare diseases. Several of its portfolio companies have advanced assets into the clinic or achieved FDA approvals/acquisitions. Representative results include IPOs (Evelo Biosciences), major acquisitions (AskBio by Bayer in 2020), and ongoing clinical trials at various stages.

Therapeutic areas: OncologyPulmonologyRare DiseasesImmunologyNeurology
Modalities: Small moleculeMonoclonal antibodyCell therapyRadiopharmaceuticalsGene therapyOncolytic virus therapy
Industry: Investors

Partnerships

Eli Lilly/Aktis OncologySanofi/Vigil NeuroscienceAstraZeneca/TeneoTwo acquisitionMerck/Peloton Biotherapeutics acquisition

Beyond the preview

Go deeper on Vida Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vida Ventures.

Explore the full profile